Income Statement
PASITHEA THERAPEUTICS CORP.
KTTA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | 0.49 | 0.02 |
|
Cost of Revenue
|
- | - | - | 0.11 | 0.02 |
|
Gross Profit
|
- | - | - | 0.37 | 0.00 |
|
Operating Expenses
|
20.86 | 14.25 | 15.98 | 15.19 | 4.51 |
|
Research & Development
|
7.98 | 7.20 | 8.10 | 2.67 | - |
|
Selling, General & Administrative
|
12.88 | 7.05 | 7.88 | 12.52 | 4.51 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-20.86 | -14.25 | -15.98 | -14.82 | -4.51 |
|
Non-Operating Income
|
0.43 | 0.35 | -0.47 | -0.88 | 2.33 |
|
Interest Income
|
0.33 | 0.42 | 0.42 | - | - |
|
Interest Expense
|
- | - | - | 0.00 | - |
|
Other Non-Op Income / Expense
|
0.38 | - | 0.47 | - | - |
|
Income Before Tax
|
-20.43 | -13.90 | -15.51 | -13.94 | -2.17 |
|
Income Tax Expense
|
0.00 | 0.00 | 0.45 | 0.00 | 0.00 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-20.43 | -13.90 | -15.96 | -13.94 | -2.17 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-20.86 | -14.25 | -15.98 | -14.82 | -4.51 |
|
Earnings Per Share (Basic)
|
-2.91 | - | -0.42 | -0.55 | -0.21 |
|
Diluted EPS
|
-2.91 | - | -0.42 | - | - |
|
Weighted Average Shares
|
7.03 | 1.10 | 1.23 | 25.25 | 10.40 |
|
Diluted Weighted Avg Shares
|
7.03 | 1.10 | 1.23 | - | - |
|
Comprehensive Income
|
-20.41 | -13.91 | -15.97 | -13.93 | -2.18 |